Neoplasms

Symptoms and General Pathology

All Conditions

Rare Diseases

Neoplasm Metastasis

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor

Neuroepithelioma

Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.

Metastatic gastroenteropancreatic and lung neuroendocrine tumors

THOMAS WALTER, Dr

EMILIE PROME

Neuroendocrine tumours (NETs) are rare and include a heterogeneous group of neoplasms derived from the endocrine system found in the gastrointestinal tract, pancreas and lung. Gastroenteropancreatic (GEP) NETs represent the majority of neuroendocrine neoplasms (NEN) and the annual incidence of all GEP-NETs has been estimated to 6.98 per 100,000 person-years in 2012 and is steadily rising. While data on the incidence of metastatic GEP-NET is limited, more than 50% of patients with GEP-NET have metastatic disease at the time of diagnosis. Incorrect and delayed diagnoses are still common. Treatment options include surgery, locoregional interventions, and systemic treatment.

The Lyon Real world Evidence in Metastatic NeuroEndocrine Tumours study (LyREMeNET) is a descriptive observational cohort study. The main objective is to assess the healthcare resources use and the corresponding costs for management of patients with metastatic GEP and lung NETs. The secondary objective is to describe the clinical characteristics, prognostic factors, treatment patterns, and the overall survival among patients with metastatic GEP and lung NETs.

The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours

Number of interventional and systemic treatments

Cumulative duration in months of systemic treatments

Hospices Civils de Lyon

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours	NCT03863106	Gastro-enteropa... Health Care Cos... Metastatic Canc...	Metastatic gast...	15 Years - 100 Years	Hospices Civils de Lyon
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours	NCT03863106	Gastro-enteropa... Health Care Cos... Metastatic Canc...	Metastatic gast...	15 Years - 100 Years	Hospices Civils de Lyon

Spots Global Cancer Trial Database for metastatic gastroenteropancreatic and lung neuroendocrine tumors